Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-07T20:27:53.527Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Paramyotonia Congenita with Acetazolamide

Published online by Cambridge University Press:  18 September 2015

Timothy J. Benstead ,
Peter R. Camfield  and
David B. King
Timothy J. Benstead*
Affiliation:
Department of Internal Medicine, Victoria General Hospital, Dalhousie University, Halifax, Nova Scotia
Peter R. Camfield
Affiliation:
Department of Pediatrics, Izaak Walton Killam Hospital for Children, Dalhousie University, Halifax, Nova Scotia
David B. King
Affiliation:
Department of Internal Medicine, Victoria General Hospital, Dalhousie University, Halifax, Nova Scotia
*
Division of Neurology, Victoria General Hospital, 1278 Tower Road, Halifax, Nova Scotia, Canada B3H 2Y9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Treatment of paramyotonia congenita with acetazolamide has been shown to reduce myotonic symptoms but severe weakness has developed in some patients leading to a recommendation not to use the drug in this disorder. We studied a patient with the characteristic clinical and electrophysiological profile of paramyotonia congenita. Myotonia was effectively treated with a very low dose of acetazolamide and no weakness developed. We conclude that acetazolamide can be a safe and effective medication in paramyotonia congenita.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue 2 , May 1987 , pp. 156 - 158
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

1.Eulenburg, A. Ubereinefamiliaredurch6Generationenverfolgbare Form congenitaler Paramyotonie. Neurologisches Centralblatt 1886; 5: 265–272.Google Scholar
2.Julien, J, Vital, C, Vallat, JM, Martin, F. Paramyotonie d’Eulenburg. J Neurol Sci 1971; 13:447–458.CrossRefGoogle Scholar
3.Riggs, JE, Griggs, RC, Moxley, RT III. Acetazolamide-induced weakness in paramyotonia congenita. Ann Int Med 1977; 86: 169–173.CrossRefGoogle ScholarPubMed
4.Brooke, MH. Paramyotonia Congenita. In: A Clinicians View of Neuromuscular Disorders. Second Edition. Baltimore: Williams andWilkins 1986; 210–211.Google Scholar
5.Becker, PE. Genetic Approaches to the Nosology of Muscle Disease: Myotonias and Similar Diseases. Birth Defects: Original Article Series 1971; 7(2): 52–62.Google Scholar
6.Haass, A, Ricker, K, Rudel, R, Lehmann-Horn, F, Bohlen, R, Dengler, R, Mertens, HG. Clinical study of paramyotonia congenita with and without myotonia in a warm environment. Muscle and Nerve 1981; 4: 388–395.CrossRefGoogle Scholar
7.Subramony, SH, Malhotra, CP, Mishra, SK. Distinguishing paramyotonia congenita and myotonia cogenita by electromyography. Muscle and Nerve 1983; 6: 374–379.CrossRefGoogle Scholar
8.Nielsen, VK, Friis, ML, Johnsen, T. Electromyographic distinction between paramyotonia congenita and myotonia congenita: Effect of cold. Neurology (New York) 1982; 32: 827–832.CrossRefGoogle ScholarPubMed
9.Ricker, K, Hertel, G, Langscheid, K, Stodieck, G. Myotonia not aggravated by cooling. Force and relaxation of the Adductor Pollicis in normal subjects and in myotonia as compared to paramyotonia. J Neurol 1977; 216: 2–20.Google Scholar
10.French, EB, Kilpatrick, R. A variety of paramyotonia congenita. J Neurol Neurosurg Psychiatry 1957; 20: 40–46.CrossRefGoogle ScholarPubMed
11.Gamstorp, I. Adynamia episodica hereditaria and myotonia. Acta Neurol Scand 1963; 39:41–58.CrossRefGoogle ScholarPubMed
12.Ricker, K, Bohlen, R, Bohkamm, R. Different effectiveness of tocainide and hydrochlorothiazide in paramyotonia congenita with hyperkalemic periodic paralysis. Neurology (Cleveland) 1983; 33: 1615–1618.CrossRefGoogle Scholar
13.Ricker, K, Haass, A, Rudel, R, Bohlen, R, Mertens, HG. Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide. J Neurol, Neurosurg, & Psychiatry 1980; 43:268–271.CrossRefGoogle Scholar
14.Griggs, RC, Moxley, RT III, Riggs, JE, Engel, WK. Effects of Acetazolamine on myotonia. Ann Neurol 1978; 3: 531–537.CrossRefGoogle Scholar
15. Horn, HR, Hadidian, Z, Johnson, JL, Vassallo, HG, Williams, JH, Young, MD. Safety evaluation of tocainide in the American Emergency Use Program. Am Hear J 1980; 100: 1037–1040.CrossRefGoogle ScholarPubMed
16.Volosin, K, Greenberg, RM, Greenspon, AJ. Tocainide associated agranulocytosis. Am Heart J 1985; 109: 1392–1393.CrossRefGoogle ScholarPubMed
17.Perlow, GM, Jain, BP, Pauker, SG, Zarren, HS, Wistran, DC, Epstein, RL. Tocainide-associated interstitial pneumonitis. Ann Intern Med 1981; 94:489–490.CrossRefGoogle ScholarPubMed
18.Farquhar, DL, Davidson, NM. Possible hepatotoxicity of tocainide. Scott Med J 1984; 29: 238.CrossRefGoogle Scholar
19.Mudge, GH. Diuretics and other agents employed in the mobilization of edema fluid (chap 36). In: Gilman, AG, Goodman, LS, Gilman, A, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Sixth edition. MacMillan Publishing Co., Inc., 1980: 899.Google Scholar
20.Parfitt, AM. Acetazolamide and Sodium Bicarbonate Induced Nephrocalcinosis and Nephrolithiasis. Arch Intern Med 1969; 124: 736–740.CrossRefGoogle ScholarPubMed
21.Layzer, RB, Lovelace, RE, Rowland, LP. Hyperkalemic Periodic Paralysis. Arch Neurol 1967; 16: 455–472.CrossRefGoogle ScholarPubMed